Step Pharma Overview

  • Founded
  • 2014
Founded
  • Status
  • Private
  • Employees
  • 12
Employees
  • Latest Deal Type
  • 2ndary - Private
  • Investors
  • 10

Step Pharma General Information

Description

Developer of proprietary small molecule therapeutics designed for the treatment of auto-immune diseases. The company's therapeutics uses a novel class of oral nucleotide synthesis inhibitors that can target CTPS1 (cytidine triphosphate synthase 1) to induce selective modulation of specific immune cell populations such as T and B cells, translating to better efficacy and an improved therapeutic index, enabling healthcare providers in proper treatment of auto-immune diseases.

Contact Information

Website
www.step-ph.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Primary Office
  • Forum 2
  • 218 avenue Marie Curie
  • 74160 Archamps
  • France
+33 0 000 00 00 00

Step Pharma Timeline

2019202020212022
Financing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Step Pharma Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
8. Secondary Transaction - Private 000.00 Completed Pre-Clinical Trials
7. Later Stage VC (Series B) 24-Mar-2021 000.00 000.00 Completed Pre-Clinical Trials
6. Early Stage VC 16-Dec-2018 00.000 000.00 000.00 Completed Pre-Clinical Trials
5. Early Stage VC (Series A) 21-Nov-2017 000.00 000.00 000.00 Completed Startup
4. Early Stage VC 28-Jul-2015 00000 00.000 00.000 Completed Startup
3. Accelerator/Incubator 24-Nov-2014 00.000 Completed Startup
2. Seed Round 30-Jul-2014 $3.39M $3.39M 000.00 Completed Startup
1. Joint Venture Completed Startup
To view Step Pharma’s complete valuation and funding history, request access »

Step Pharma Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Ordinary 0,000,000 00.000000 00.0 00.0 00 00.0 00.00
Series A 0,000,000 00.000000 00.0 00.0 00 00.0 00.000
Series A 2,935,873 $0.113658 $2.27 $2.27 1x $2.27 38.76%
Ordinary 1,250,000 $0.113658 $2.27 $2.27 1x $2.27 16.5%
To view Step Pharma’s complete cap table history, request access »

Step Pharma Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of proprietary small molecule therapeutics designed for the treatment of auto-immune diseases. The company's t
Drug Discovery
Archamps, France
12 As of 2021
000.00
000000 - 000 000.00

0000000

laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate
0000 000000000
Philadelphia, PA
00 As of 0000
00000
0000 0000-00-00
00000000000 00000

000000

rcitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehen
0000000000000
Utrecht, Netherlands
00 As of 0000
00.000
0000000000 0 00.000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Step Pharma Competitors (44)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Carisma Therapeutics Venture Capital-Backed Philadelphia, PA 00 00000 00000000000 00000
000000 Venture Capital-Backed Utrecht, Netherlands 00 00.000 0000000000 0 00.000
000000000 Formerly VC-backed Gaithersburg, MD 00 00000 00000000 00000
000000 Venture Capital-Backed Lebanon, NH 000 00000 000000 - 000 00000
00000000 Formerly VC-backed Tübingen, Germany 000 00000 000000000 00000
You’re viewing 5 of 44 competitors. Get the full list »

Step Pharma Patents

Step Pharma Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
CA-3115568-A1 Aminopyrimidine/pyrazine derivatives as ctps1 inhibitors Pending 23-Oct-2018 0000000000
AU-2019367191-A1 Aminopyrimidine/pyrazine derivatives as ctps1 inhibitors Pending 23-Oct-2018 0000000000
EP-3870574-A1 Aminopyrimidine/pyrazine derivatives as ctps1 inhibitors Pending 23-Oct-2018 0000000000
EP-3578551-A1 Sulfonamide derivatives Ceased 04-Jun-2018 0000000000 0
CA-3093050-A1 Aminopyrimidine derivatives as ctps1 inhibitors Pending 23-Mar-2018 C07D405/14
To view Step Pharma’s complete patent history, request access »

Step Pharma Executive Team (9)

Name Title Board Seat Contact Info
Nicolas Marsault Chief Financial Officer
Duc Tran Chief Development Officer
Alain Fischer Ph.D Scientific Co-Founder
Sylvain Latour Scientific Co-Founder
Andrew Parker Ph.D Chief Executive Officer & President
You’re viewing 5 of 9 executive team members. Get the full list »

Step Pharma Board Members (13)

Name Representing Role Since
Adrian Senderowicz MD Self Board Member 000 0000
Erik van den Berg Self Chairman 000 0000
François Thomas MD Inserm Transfert Board Member 000 0000
Jacky Vonderscher Ph.D Self Board Member 000 0000
Jacob Lange Moresco Ph.D Sunstone Life Science Ventures Board Member 000 0000
You’re viewing 5 of 13 board members. Get the full list »

Step Pharma Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Step Pharma Investors (10)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Hadean Ventures Venture Capital Minority 000 0000 000000 0
Sunstone Life Science Ventures Venture Capital Minority 000 0000 000000 0
Sofimac Innovation Venture Capital Minority 000 0000 000000 0
Imagine Institute Corporation Minority 000 0000 000000 0
Pontifax Venture Capital Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 10 investors. Get the full list »